secwatch.observer — SEC 8-K summary
======================================

Issuer:     PRECISION BIOSCIENCES INC (DTIL)
CIK:        0001357874
Form:       8-K
Filed at:   2023-08-04T23:59:59+00:00
Accession:  0000950170-23-038328
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Precision BioSciences Q2 net loss narrows to $11.9M; FDA clarity on azer-cel; cash through Q1 2025
--------------------------------------------------------------------------------

- Net loss of $11.9M ($0.10 per share) vs $31.0M ($0.46) in Q2 2022; revenue $19.8M from $3.8M on Prevail amendment.
- Cash and equivalents $137.8M; expected runway through Q1 2025 without additional funding.
- FDA Type B meeting provided clarity on azer-cel registration path; partnering discussions underway for cell therapy assets.
- In vivo gene editing programs progressing: PBGENE-HBV plans IND/CTA in 2024; PBGENE-DMD shows proof-of-concept; Novartis and Prevail collaborations ongoing.
- Company to host In Vivo Gene Editing R&D Day on September 12, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1357874/000095017023038328/0000950170-23-038328-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1357874/000095017023038328/dtil-20230804.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-038328

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer